Corporate Finance
Bergs Securities is proud to have acted as certified adviser and financial advisor to Axvik Group in its IPO on Nasdaq First North Growth Market
Bergs Securities acted as sole manager and bookrunner to Modus Therapeutics Holding AB in its oversubscribed SEK 28 million rights issue
Corporate Finance
Bergs Securities acted as sole manager and bookrunner to Modus Therapeutics Holding AB in its oversubscribed SEK 28 million rights issue.
Modus Therapeutics Holding AB is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis/septic shock and other disorders with severe systemic inflammation such as severe malaria, as well as states of anemia, related to chronic inflammation such as kidney disease.
Related News
Company news
Bergs securities granted additional authorisations by the swedish financial supervisory authority
Company news
Bergs Securities recruits Jonathan Hedin to its Corporate Finance team